
Woonyoung Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10886136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell, 2014, 25, 152-165.	7.7	1,358
2	Bladder cancer. Lancet, The, 2016, 388, 2796-2810.	6.3	1,031
3	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research, 2009, 69, 5820-5828.	0.4	771
4	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
5	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2017, 72, 544-554.	0.9	638
6	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	3.2	386
7	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer and Metastasis Reviews, 2009, 28, 335-344.	2.7	324
8	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Reviews Urology, 2014, 11, 400-410.	1.9	267
9	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naÃ ⁻ ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer, European Urology, 2016, 69, 855-862.	0.9	228
10	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. European Urology, 2017, 72, 354-365.	0.9	195
11	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 429-440.	0.8	188
12	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology, 2016, 70, 611-620.	0.9	120
13	The p63 Protein Isoform ΔNp63α Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells. Journal of Biological Chemistry, 2013, 288, 3275-3288.	1.6	116
14	Molecular Subtypes of Bladder Cancer. Current Oncology Reports, 2018, 20, 77.	1.8	111
15	Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	3.2	98
16	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	1.6	83
17	Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines. Clinical Cancer Research, 2009, 15, 532-542.	3.2	76
18	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE, 2012, 7, e30206.	1.1	71

WOONYOUNG CHOI

#	Article	IF	CITATIONS
19	Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting. PLoS ONE, 2013, 8, e57284.	1.1	68
20	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 377-394.	0.9	57
21	New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. European Urology, 2014, 66, 609-610.	0.9	55
22	Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells. Journal of Biological Chemistry, 2005, 280, 3295-3304.	1.6	48
23	The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. Clinical Cancer Research, 2020, 26, 4018-4030.	3.2	44
24	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2021, 79, 364-371.	0.9	41
25	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 80164-80174.	0.8	40
26	Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. PLoS ONE, 2013, 8, e69509.	1.1	35
27	Genetic subtypes of invasive bladder cancer. Current Opinion in Urology, 2015, 25, 449-458.	0.9	35
28	Intrinsic subtypes and bladder cancer metastasis. Asian Journal of Urology, 2016, 3, 260-267.	0.5	31
29	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports, 2019, 26, 2241-2256.e4.	2.9	31
30	Update on bladder cancer molecular subtypes. Translational Andrology and Urology, 2020, 9, 2881-2889.	0.6	28
31	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology, 2018, 1, 54-60.	2.6	26
32	Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biology and Therapy, 2006, 5, 1450-1456.	1.5	20
33	p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 477-486.	1.5	18
34	A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biology and Therapy, 2013, 14, 812-822.	1.5	18
35	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	1.9	18
36	Inactivation of IκB contributes to transcriptional activation of spermidine/spermine N (1)-acetyltransferase. Molecular Carcinogenesis, 2006, 45, 685-693.	1.3	14

WOONYOUNG CHOI

#	Article	IF	CITATIONS
37	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget, 2017, 8, 34205-34222.	0.8	13
38	Tumor heterogeneity in muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2866-2880.	0.6	11
39	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology, 2021, 206, 548-557.	0.2	9
40	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	9
41	Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget, 2017, 8, 51675-51687.	0.8	8
42	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	0.8	5
43	Subtyping Bladder Cancers: Biology vs Bioinformatics. Journal of the National Cancer Institute, 2018, 110, 439-440.	3.0	4
44	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Molecular Cancer Research, 2020, 18, 811-821.	1.5	4
45	A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer Journal of Clinical Oncology, 2018, 36, 519-519.	0.8	4
46	Role of immunotherapy in localized muscle invasive urothelial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045858.	1.4	4
47	Molecular Characterization of Pancreatic Cancer Cell Lines. , 2010, , 457-469.		3
48	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609–10. European Urology, 2015, 67, e76-e78.	0.9	3
49	ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers. European Urology, 2019, 75, 240-241.	0.9	2
50	Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology, 2021, 156, 104-109.	0.5	2
51	Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354–65. European Urology. 2018. 73. e104-e105.	0.9	1
52	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology, 2020, 77, 436-438.	0.9	1
53	Understanding Cancer through Proteomics. Technology in Cancer Research and Treatment, 2002, 1, 221-230.	0.8	0

54 Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2018, , 369-382.

0

0

#	Article	IF	CITATIONS
55	Editorial: Recent Advances in Diagnosis and Management of Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 656974.	1.3	0

Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2017, , 1-14.